None of the babies that received a placebo did. The F. D. A. approved the drug months ahead of time and, because the drug treats a rare pediatric disease, granted Biogen a special voucher that it can use to gain priority review of a future drug that would not otherwise qualify for the program. The F. D. A. said the most common side effects were respiratory infections and constipation, and there is a warning about possible low blood platelet counts and toxicity to the kidneys. Even though trial investigators did not know which patient was receiving Spinraza, "anecdotally, it just seemed quickly obvious to us that some patients were following a very different trajectory than what we were used to seeing," said Dr. John Brandsema of the Childrenâ€™s Hospital of Philadelphia, one of the investigators. 